Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Acta2-cre/ERT2)#Pcn mutation
(0 available)
Tgfbr2tm1Karl mutation
(1 available);
any
Tgfbr2 mutation
(39 available)
Tg(H2-K-Fosl2,-EGFP)13Wag mutation
(0 available)
|
|
|
respiratory system
|
|
• mice treated with tamoxifen show similar lung inflammation as single Tg(H2-K-Fosl2,EGFP)13Wag mice
|
|
|
• mice treated with tamoxifen show similar pulmonary fibrosis as single Tg(H2-K-Fosl2,EGFP)13Wag mice
|
immune system
|
|
• mice treated with tamoxifen show similar lung inflammation as single Tg(H2-K-Fosl2,EGFP)13Wag mice
|
cardiovascular system
|
N |
• mice treated with tamoxifen show diminished expansion of the smooth muscle cell area in pulmonary arteries and reduced proliferation of pulmonary artery smooth muscle cells that is seen in single Tg(H2-K-Fosl2,EGFP)13Wag mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nr3c2tm1.1Ics mutation
(1 available);
any
Nr3c2 mutation
(51 available)
Tg(Acta2-cre/ERT2)#Pcn mutation
(0 available)
|
|
|
cardiovascular system
|
N |
• tamoxifen-treated mice exhibit normal vascular structure and blood pressure response to altered sodium content diets
|
|
|
• aged tamoxifen-treated mice do not develop cardiac hypertrophy unlike control mice
|
|
|
• in tamoxifen-treated mice by 7 months of age
• in adult and aged tamoxifen-treated mice in response to Ang II
• however, diurnal blood pressure variation is normal
|
|
|
• aged tamoxifen-treated mice fail to exhibit an increase in contraction response to KCL or U46619 (thromboxane receptor agonist) unlike control mice
• however, the age-dependent increase in contraction response to phenylephrine is preserved
|
|
|
• in tamoxifen-treated mice in response to phenylephrine
• in adult tamoxifen-treated mice in response to acetylcholine
• in aged tamoxifen-treated mice in response to BayK8644 (L-type calcium channel agonist)
• in adult and aged tamoxifen-treated mice in response to Ang II
|
|
|
• in aged tamoxifen-treated mice in response to sodium nitroprusside
|
|
|
• aged tamoxifen-treated mice exhibit a modest decrease in endothelial cell-independent vasodilation compared with control mice
|
|
|
• endothelial-dependent tamoxifen-treated mice
|
renal/urinary system
|
N |
• tamoxifen-treated mice exhibit intact renal function
|
cellular
|
|
• adult tamoxifen-treated mice exhibit attenuated AngII-stimulated reactive oxygen species production compared with control mice
• aged tamoxifen-treated mice exhibit attenuated reactive oxygen species production prior to and after AngII-stimulation compared with control mice
|
muscle
|
|
• aged tamoxifen-treated mice fail to exhibit an increase in contraction response to KCL or U46619 (thromboxane receptor agonist) unlike control mice
• however, the age-dependent increase in contraction response to phenylephrine is preserved
|
|
|
• in tamoxifen-treated mice in response to phenylephrine
• in adult tamoxifen-treated mice in response to acetylcholine
• in aged tamoxifen-treated mice in response to BayK8644 (L-type calcium channel agonist)
• in adult and aged tamoxifen-treated mice in response to Ang II
|
|
|
• in aged tamoxifen-treated mice in response to sodium nitroprusside
|
|
|
• aged tamoxifen-treated mice exhibit a modest decrease in endothelial cell-independent vasodilation compared with control mice
|
|
|
• endothelial-dependent tamoxifen-treated mice
|
|
|
• aged tamoxifen-treated mice develop less spontaneous myogenic tone compared with control mice
|
Analysis Tools